ATHIRA PHARMA INC. - COMMON STOCK

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

06 12 2024 16:30:00 提供 Nasdaq GlobeNewswire

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

07 11 2024 15:05:02 提供 Nasdaq GlobeNewswire

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

22 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

17 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

03 9 2024 15:01:00 提供 Nasdaq GlobeNewswire

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

01 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024

31 7 2024 07:05:00 提供 Nasdaq GlobeNewswire

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

09 7 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients

12 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

11 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming June Conferences

29 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

17 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

15 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming May Conferences

02 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

15 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

11 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

03 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

08 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

22 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

08 2 2024 15:02:00 提供 Nasdaq GlobeNewswire